Best Biologic for Crohn's Disease: How to Choose

Quick answer: There is no single "best" biologic for Crohn's disease. The right choice depends on how severe and where your disease is, whether you have fistulas, which treatments you have already tried, the drug's safety profile, how it is given (infusion versus injection versus pill), and your own preferences. Major guidelines now recommend several high-efficacy options as reasonable first choices rather than naming one winner, and they stress that the decision should be made jointly by you and your gastroenterologist [1].

Key Takeaways

• Guidelines do not crown one biologic as best. The 2021 AGA guideline recommended infliximab, adalimumab, or ustekinumab over certolizumab pegol for biologic-naive patients, and the 2025 update lists several high-efficacy options as appropriate first choices [1][2].
• A large network meta-analysis suggested infliximab plus azathioprine or adalimumab may be preferred first-line for inducing remission, while adalimumab (after infliximab) or risankizumab may be preferred second-line [3].
• For perianal fistulizing Crohn's, infliximab has the strongest evidence and is recommended as a first-line biologic [4][5].
• In the head-to-head SEQUENCE trial, risankizumab was noninferior to ustekinumab for clinical remission and superior for endoscopic remission [6].
• Vedolizumab is gut-selective and has a favorable safety profile, with low rates of serious infections in long-term data [7].
• Upadacitinib is an oral small molecule (a different class) approved for moderate-to-severe Crohn's after inadequate response or intolerance to one or more TNF blockers [8].

The Main Biologic Options for Crohn's

Biologics are protein-based drugs that target specific parts of the immune system driving inflammation. The main classes used in Crohn's disease are grouped below, with upadacitinib included as an oral alternative.

Anti-TNF agents (infliximab, adalimumab)

Anti-TNF drugs block tumor necrosis factor, a key inflammatory signal. They are the longest-studied biologics in Crohn's and have robust evidence across luminal and fistulizing disease. Infliximab is given by intravenous infusion (a subcutaneous form also exists), and adalimumab is a self-administered injection. Infliximab is the most established option for perianal fistulas [4][5].

Anti-integrin (vedolizumab)

Vedolizumab blocks the alpha-4-beta-7 integrin, preventing inflammatory white blood cells from entering the gut. Because it acts mainly in the intestine rather than throughout the body, it is described as gut-selective and has a favorable safety profile with low rates of serious infections in pooled long-term data [7]. It is given by infusion or subcutaneous injection. For more detail, see our vedolizumab (Entyvio) patient guide.

Anti-IL-12/23 (ustekinumab)

Ustekinumab targets the p40 subunit shared by interleukin-12 and interleukin-23. It is given as an initial infusion followed by subcutaneous injections and has a well-regarded safety record. In the biologic-naive setting, the AGA placed it among the recommended first-line agents [2].

Anti-IL-23 (risankizumab)

Risankizumab selectively blocks the p19 subunit of interleukin-23 and is one of several IL-23 inhibitors now approved for Crohn's disease. It is a newer option with strong trial data, including the only large head-to-head study against another biologic in Crohn's. It is given as induction infusions followed by subcutaneous maintenance injections. For a deeper comparison, see our guide on Skyrizi versus Stelara for Crohn's disease.

Oral small molecule alternative (upadacitinib)

Upadacitinib is not a biologic but an oral JAK inhibitor, a different class taken as a once-daily pill. The FDA approved it for moderate-to-severely active Crohn's in adults with an inadequate response or intolerance to one or more TNF blockers [8]. It is often considered alongside biologics when route and speed of onset matter.

How the Options Compare

| Drug | Target / class | Route | Who it may suit | | --- | --- | --- | --- | | Infliximab | Anti-TNF | IV infusion (or subcutaneous) | Severe or fistulizing disease; strong fistula evidence [4][5] | | Adalimumab | Anti-TNF | Subcutaneous injection | Those wanting at-home dosing; first-line candidate [3] | | Vedolizumab | Anti-integrin (gut-selective) | Infusion or injection | Those prioritizing a favorable safety profile [7] | | Ustekinumab | Anti-IL-12/23 | Infusion then injection | Biologic-naive or anti-TNF failures; recommended option [2] | | Risankizumab | Anti-IL-23 | Infusion then injection | Strong head-to-head and second-line data [3][6] | | Upadacitinib | Oral JAK inhibitor (different class) | Once-daily pill | Those wanting an oral option after anti-TNF [8] |

What Does the Head-to-Head Evidence Show?

Direct head-to-head trials between biologics in Crohn's are rare, which is why no drug can be called universally best. The most important comparison is the SEQUENCE trial, which pitted risankizumab against ustekinumab in patients who had failed anti-TNF therapy. Both primary endpoints were met: risankizumab was noninferior to ustekinumab for clinical remission at week 24 (58.6 percent versus 39.5 percent) and superior for endoscopic remission at week 48 (31.8 percent versus 16.2 percent) [6].

Beyond that single trial, most comparisons come from network meta-analyses, which combine many placebo-controlled studies to estimate relative effects indirectly. A 2021 systematic review and network meta-analysis in The Lancet Gastroenterology and Hepatology concluded that, among biologic-naive patients, infliximab plus azathioprine or adalimumab might be preferred for inducing remission, while among biologic-exposed patients, adalimumab (after infliximab loss of response) or risankizumab might be preferred [3]. These are indirect estimates, not direct contests, so they guide positioning rather than declare a clear champion.

What Factors Decide the Choice?

Disease severity and location

More severe disease often calls for the highest-efficacy options early. The 2025 AGA guideline emphasizes starting advanced therapy promptly rather than slowly stepping up, and lists several high-efficacy agents (including infliximab, adalimumab, ustekinumab, and risankizumab) as appropriate choices [1].

Fistulizing disease

If you have perianal fistulas, infliximab has the strongest and longest-standing evidence and is recommended first-line for this situation by major guidelines [4][5]. This is one of the clearest cases where the disease feature points toward a specific drug.

Safety profile

Safety matters, especially with other health conditions. Vedolizumab acts mainly in the gut and has shown low rates of serious infections in long-term safety data, which can make it attractive for older patients or those at higher infection risk [7]. Every drug carries its own risks, so this is a conversation to have with your GI.

Route and frequency

Some people strongly prefer a pill or an at-home injection over regular infusions, while others prefer the structure of infusion visits. Adalimumab and the maintenance phases of ustekinumab and risankizumab are injections, infliximab is typically an infusion, and upadacitinib is a daily pill [8]. Patient preference is a legitimate and important factor.

Prior anti-TNF use

If you have already tried and failed an anti-TNF drug, the evidence shifts. Network meta-analysis data suggest risankizumab or switching within the anti-TNF class (adalimumab after infliximab) may be preferred in biologic-exposed patients, and the SEQUENCE trial specifically studied an anti-TNF-failure population [3][6].

First Line Versus Later Line: Does Order Matter?

Yes. A drug that performs well in someone who has never had a biologic may behave differently in someone who has already lost response to one. That is why guidelines and network meta-analyses analyze biologic-naive and biologic-exposed patients separately [3]. In practice, your treatment history is one of the biggest factors steering which agent comes next. The broader trend in modern guidelines is toward using effective therapy earlier rather than cycling slowly through weaker options [1].

Why Shared Decision-Making Matters

Because there is no objectively best biologic, the right answer is the one that fits your disease and your life. Shared decision-making means your gastroenterologist brings the evidence on efficacy, safety, and your specific disease features, and you bring your priorities (needle versus pill, visit frequency, work and travel, family planning, and tolerance for risk). The major guidelines explicitly frame these as individualized decisions to be made together [1][3].

Frequently Asked Questions

Is there one best biologic for Crohn's disease?

No. Guidelines recommend several high-efficacy options rather than naming a single best drug, because the right choice depends on your disease and preferences [1][2].

Which biologic is best for fistulas?

Infliximab has the strongest evidence for perianal fistulizing Crohn's and is recommended as a first-line biologic for this situation [4][5].

Is risankizumab better than ustekinumab?

In the SEQUENCE trial, risankizumab was noninferior for clinical remission and superior for endoscopic remission compared with ustekinumab in anti-TNF-failure patients. That is one trial in one population, not a blanket ranking [6].

Which biologic is the safest?

Safety depends on the individual, but vedolizumab is gut-selective and has shown a favorable safety profile with low rates of serious infections in long-term data [7]. Discuss your personal risks with your GI.

Can I take a pill instead of an infusion or injection?

Upadacitinib is an oral once-daily option approved for adults who have not responded to or could not tolerate one or more TNF blockers. It is a different class from biologics [8].

What if my first biologic stops working?

Loss of response is common and the evidence changes once you have been exposed to a biologic. Options such as risankizumab or switching agents are studied specifically in biologic-exposed patients [3][6].

Does starting a biologic early matter?

Modern guidelines favor using effective therapy earlier rather than slowly stepping up, which can improve outcomes in moderate-to-severe disease [1].

This article is for educational purposes only and is not medical advice. Treatment decisions for Crohn's disease should be made with your gastroenterologist, who can weigh your specific disease, history, and preferences.

References

1. AGA unveils new clinical practice guideline for Crohn's disease (2025). https://news.gastro.org/issues/2025/november/aga-unveils-new-clinical-practice-guideline-for-crohns-disease/
2. Feuerstein JD, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Crohn's Disease. Gastroenterology. 2021. https://www.gastrojournal.org/article/S0016-5085(21)00645-4/fulltext
3. Singh S, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021. https://pubmed.ncbi.nlm.nih.gov/34688373/
4. AGA. Medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. https://gastro.org/clinical-guidance/medical-management-of-moderate-to-severe-luminal-and-perianal-fistulizing-crohns-disease/
5. Sands BE, et al. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease (ACCENT II). N Engl J Med. 2004. https://www.nejm.org/doi/full/10.1056/NEJMoa030815
6. Peyrin-Biroulet L, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE). N Engl J Med. 2024. https://pubmed.ncbi.nlm.nih.gov/39018531/
7. Colombel JF, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017. https://pubmed.ncbi.nlm.nih.gov/26893500/
8. U.S. FDA Approves RINVOQ (upadacitinib) for Moderately to Severely Active Crohn's Disease in Adults. AbbVie. 2023. https://news.abbvie.com/2023-05-18-U-S-FDA-Approves-RINVOQ-R-upadacitinib-as-a-Once-Daily-Pill-for-Moderately-to-Severely-Active-Crohns-Disease-in-Adults